Immunogen, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.3Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
1,989clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Helen Thackray | Washington, DC | Pediatrics | $543,947.66 |
| Robert Morris | Detroit, MI | Gynecologic Oncology | $46,654.33 |
| Edward Tanner | Washington, DC | Gynecologic Oncology | $34,485.32 |
| Chirag Shah | Seattle, WA | Gynecologic Oncology | $33,556.93 |
| Thomas Krivak | Pittsburgh, PA | Gynecologic Oncology | $33,191.19 |
| Heidi Godoy | Albany, NY | Gynecologic Oncology | $32,743.21 |
| Sharyn Lewin | Teaneck, NJ | Gynecologic Oncology | $24,584.13 |
| Ruchi Garg | Newnan, GA | Gynecologic Oncology | $22,817.74 |
| Gottfried Konecny | Los Angeles, CA | Hematology & Oncology | $20,177.14 |
| Mark Shahin | Hershey, PA | Gynecologic Oncology | $19,632.72 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.